Rare Diseases: Drugs
Commons · Question 69241 · Tabled 21 Jul 2025 · Department of Health and Social Care · Official record
Answered 1 Sep 2025
Question
Asked by Jim Shannon
To ask the Secretary of State for Health and Social Care, with reference to the NHS commercial framework for new medicines, updated on 29 January 2025, what assessment he has made of the potential impact of the requirement to provide value at or below the
Answer
Answered by Karin Smyth, 1 Sep 2025
Indication-specific pricing can support access to treatments, including for rare conditions, by enabling companies to propose a specific price for smaller indications that would otherwise be commercially unviable under a uniform price.In January 2025, fol...